Novartis AG (NVS)
98.35
+1.07
(+1.10%)
USD |
NYSE |
Apr 24, 16:00
98.79
+0.44
(+0.45%)
Pre-Market: 20:00
Novartis Enterprise Value: 211.67B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 211.67B |
| April 23, 2024 | 209.48B |
| April 22, 2024 | 205.07B |
| April 19, 2024 | 203.52B |
| April 18, 2024 | 199.86B |
| April 17, 2024 | 200.90B |
| April 16, 2024 | 201.14B |
| April 15, 2024 | 203.62B |
| April 12, 2024 | 201.80B |
| April 11, 2024 | 203.48B |
| April 10, 2024 | 203.56B |
| April 09, 2024 | 206.48B |
| April 08, 2024 | 205.81B |
| April 05, 2024 | 206.44B |
| April 04, 2024 | 208.69B |
| April 03, 2024 | 203.54B |
| April 02, 2024 | 203.62B |
| April 01, 2024 | 206.60B |
| March 28, 2024 | 208.36B |
| March 27, 2024 | 206.62B |
| March 26, 2024 | 205.38B |
| March 25, 2024 | 206.32B |
| March 22, 2024 | 207.34B |
| March 21, 2024 | 207.03B |
| March 20, 2024 | 206.97B |
| Date | Value |
|---|---|
| March 19, 2024 | 207.52B |
| March 18, 2024 | 206.70B |
| March 15, 2024 | 209.46B |
| March 14, 2024 | 211.22B |
| March 13, 2024 | 213.00B |
| March 12, 2024 | 214.57B |
| March 11, 2024 | 217.84B |
| March 08, 2024 | 216.50B |
| March 07, 2024 | 214.90B |
| March 06, 2024 | 220.44B |
| March 05, 2024 | 219.34B |
| March 04, 2024 | 219.07B |
| March 01, 2024 | 219.26B |
| February 29, 2024 | 217.03B |
| February 28, 2024 | 219.58B |
| February 27, 2024 | 221.48B |
| February 26, 2024 | 221.69B |
| February 23, 2024 | 223.02B |
| February 22, 2024 | 220.77B |
| February 21, 2024 | 220.28B |
| February 20, 2024 | 220.60B |
| February 16, 2024 | 215.43B |
| February 15, 2024 | 214.29B |
| February 14, 2024 | 213.10B |
| February 13, 2024 | 213.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
169.75B
Minimum
Oct 12 2022
246.85B
Maximum
Jan 25 2021
215.36B
Average
218.73B
Median
Mar 16 2021
Enterprise Value Benchmarks
| Sandoz Group AG | -- |
| Roche Holding AG | 221.74B |
| Amgen Inc | 199.98B |
| Incyte Corp | 7.961B |
| MorphoSys AG | 2.649B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.48B |
| Revenue (Quarterly) | 11.78B |
| Total Expenses (Quarterly) | 9.194B |
| EPS Diluted (Quarterly) | 4.06 |
| Gross Profit Margin (Quarterly) | 74.34% |
| Profit Margin (Quarterly) | 72.01% |
| Earnings Yield | 7.22% |
| Operating Earnings Yield | 4.92% |
| Normalized Earnings Yield | 4.260 |